Boehringer Ingelheim Hellas S.A
- FAX+30 210 8983207
A Quadruple Leader of the Greek Pharmaceutical Market
Pharmaceutical Boehringer Ingelheim was established in 1885 and is now among the world’s top 20 pharmaceutical companies. The company has recently been named one of the top 100 innovative companies of all industrial sectors. Meanwhile the company is launching a new R&D strategy pledging to invest a total amount of 11, 5 billion euro over the next years.
In Greece, the firm was founded in 1966 and is considered to be a market leader among the country’s top 10 drug companies, while it has awarded several times both in Greece and abroad for its successful launches of innovative products including respiratory, cardiovascular, pain management, and recently Diabetes and oncology.
Boehringer Ingelheim Hellas is also considered to be an innovation leader as it participates actively in the parent company’s international clinical research program with a total investment of 11.5 million euros in the past five years in its participation in clinical trials.
Boehringer Ingelheim Hellas SA is the only subsidiary of a multinational company in Greece that has been posting growing sales in recent years, amidst adverse conditions in the domestic market, helped primarily by its strong exports. Notably, the firm posted a high level of 2015 sales, as a result of both high exports and the returns of a 2012 investment in production facilities, now fully operational.
The company this year celebrates the 40th anniversary of the opening of its production facility in Koropi, Attica, which set new standards in the country’s industrial sector. Today, it is the only multinational pharmaceutical company that maintains its industrial production facility in Greece, supplying not only the Greek market but also the markets of more than 45 countries. Its export activity is of particular importance not only to the firm itself, but also to the country’s economy, as it accounts for about 1% of total Greek exports, establishing Boehringer Ingelheim Ellas as a production & exports leader.
Its parent company recently entrusted Boehringer Ingelheim Hellas with the production of innovative antidiabetic drugs at the Greek plant, aimed at covering a large part of its international production, which is a ‘first’ in the company’s history.
Such actions and investments in production and export activity by Boehringer Ingelheim Hellas – with exports being its strong asset, stand proof of the confidence shown by the German multinational and its intention not only to upgrade its Greek subsidiary, but also to support and boost Greek exports.
Boehringer Ingelheim Hellas’ initiatives for Greece’s economy are summarized in the triptych: “We Invest, We Grow, We Support.”
Last but not least, the firm’s human resources, more than 350 people, comprise leading scientists and sector professionals with the required skills, education and experience to implement its objectives and promote its vision, “Value through Innovation”.
In 2015, the firm posted sales of 235 million euros, with pre-tax profits rising to 5.4 million euros.